01

Evaxion to Present New EVX-01 Immune Data at SITC 2026

Evaxion will present comprehensive immune profiling of EVX-01 plus pembrolizumab at SITC on Nov. 6–7, after a 75% two-year ORR in 16 melanoma patients. A three-year ESMO update follows Oct. 24.